Study finds RSV vaccine highly effective in protecting older adults against severe disease, hospitalization and death

A multi-state research, revealed in The Lancet, is likely one of the first actual world knowledge analyses of the effectiveness of the RSV—brief for respiratory syncytial virus—vaccine. VISION Network researchers report that throughout the board these vaccines had been highly effective in older adults, even these with immunocompromising situations, through the 2023–24 respiratory illness season, the primary season after RSV vaccine approval in the U.S.

RSV vaccination offered roughly 80% safety against severe illness and hospitalization, Intensive Care Unit admission and death attributable to a respiratory an infection, in addition to related safety against much less severe illness in adults who visited an emergency division however didn’t require hospitalization, ages 60 and older. Of this inhabitants, these ages 75 and older had been at highest threat of severe illness and had been the almost certainly to be hospitalized.

The research was a collaboration between the Centers for Disease Control and Prevention (CDC) and geographically numerous U.S. well being care methods and analysis facilities with built-in medical, laboratory and vaccination data—all members of the CDC’s VISION Network.

“Unlike this knowledge research, medical trials for the RSV vaccine had been underpowered to evaluate the effectiveness of the vaccines against severe illness requiring hospitalization. Addressing this hole in proof, we had been ready to make use of the facility of massive knowledge to find out RSV vaccine effectiveness, data wanted to tell vaccine coverage,” mentioned research co-author Shaun Grannis, M.D., M.S.

“As a knowledge scientist and a household observe doctor, I encourage older adults to observe CDC steering and get vaccinated for RSV as we enter this yr’s and yearly’s respiratory illness season.”

Dr. Grannis is vice chairman for knowledge and analytics at Regenstrief Institute and a professor of household medication on the Indiana University School of Medicine.

In the U.S., respiratory illness season usually commences in late September or early October and continues by March or early April.

RSV impacts the nostril, throat and lungs, inflicting substantial sickness and death amongst older adults throughout these seasonal epidemics. In years previous to the supply of an RSV vaccine, an estimated 60,000 to 160,000 RSV-associated hospitalizations and 6,000 to 10,000 RSV-associated deaths occurred yearly amongst U.S. adults aged 65 years and older, based on the CDC.

“No vaccine is 100% effective. An 80% vaccine effectiveness price is kind of spectacular and increased than we see, for instance, with the influenza vaccine,” mentioned research co-author Brian Dixon, Ph.D., MPA.

“The backside line is that utilizing actual world knowledge from digital medical data routinely captured in take care of individuals from numerous walks of life, we discovered that having the vaccine was highly protecting against hospitalization, severe sickness and death.”

Dr. Dixon is interim director and a analysis scientist with the Clem McDonald Center for Biomedical Informatics at Regenstrief Institute and a professor on the Indiana University Indianapolis Fairbanks School of Public Health.

Dr. Dixon added, “Studies like this one are important to understanding the results of prevention methods like vaccination. The annual price of RSV hospitalization for adults in the U.S. is estimated to be between $1.2 and $5 billion. Preventing as much as 80% of hospitalizations may consequence in main financial savings for customers and the well being system.”

VISION websites taking part in the research had been Permanente Northwest (Oregon and Washington), University of Colorado (Colorado), Intermountain Health care (Utah), Regenstrief Institute (Indiana), HealthCompanions (Minnesota and Wisconsin), and Kaiser Permanente Northern California (California), representing 230 hospitals and 245 emergency departments.

Regenstrief contributes knowledge and scientific experience to the VISION Network.